您的位置: 首页 » 法律资料网 » 法律法规 »

商务部关于建立重点商品交易市场联系制度的通知

时间:2024-07-09 08:47:33 来源: 法律资料网 作者:法律资料网 阅读:9695
下载地址: 点击此处下载

商务部关于建立重点商品交易市场联系制度的通知

商务部


商务部关于建立重点商品交易市场联系制度的通知

商建发[2004]581号


  各省、自治区、直辖市及计划单列市商务主管部门:

  为加强商品交易市场建设管理与分类指导,促进商品交易市场规范、协调与可持续发展,经研究,决定建立重点商品交易市场联系制度。现将有关事项通知如下:
  
  一、建立重点商品交易市场联系制度的重要意义改革开放以来,我国商品交易市场发展迅速,其规模化、规范化、专业化及现代化水平不断提高,在引导消费、促进生产、扩大就业以及优化资源配置等方面发挥了积极的作用,对国民经济发展做出了贡献。在市场体系建设工作中,建立重点商品交易市场联系制度,发挥其引导和示范作用,有利于进一步推进商品交易市场交易方式、管理方式与制度创新,完善其集散商品、传播信息、形成价格、统一结算等服务功能;有利于提高流通效率,降低市场交易成本;有利于规范商品交易秩序,引导和促进有序竞争;有利于扩大内需、开拓市场,促进国民经济健康发展;有利于在更大程度上发挥市场在资源配置中的基础作用,健全和完善全国统一、开放、竞争、有序的现代市场体系。

  二、重点商品交易市场联系制度的基本内容
  
  (一)建立商务部与重点联系商品交易市场(以下简称重点联系市场)信息互通渠道。重点联系市场可以通过有关行业协会、省级商务主管部门或者直接向商务部反映其运行管理中出现的情况和问题。商务部委托有关行业协会每年组织1-2次重点联系市场座谈会,沟通信息,听取意见和建议,总结推广重点市场好的运行模式和成功的管理经验;利用有关刊物或以简报形式不定期向重点联系市场提供国家有关政策信息,加强政策引导。

  (二)推进重点联系市场交易升级和管理创新。重点联系市场要在遵守有关法律、法规的前提下,积极探索和推广代理、配送、电子商务等新型交易方式。不断完善公司法人治理结构,大力提高规范化管理水平。

  (三)促进重点联系市场改造升级。商务部将会同有关部门采取相应的政策措施,引导和促进重点联系市场基础设施和配套设施建设与改造。

  (四)商务部鼓励重点联系市场在有关行业协会的统一组织下,实行准入制度和健全交易监督机制,在加强商品质量管理、打击伪劣商品以及建立重点联系市场信用联盟机制和市场自律机制方面进行积极探索。

  三、重点联系市场应当具备下列条件
  
  (一)经省、自治区、直辖市、计划单列市人民政府及新疆生产建设兵团市场建设管理部门批准设立,并且设立时间在3年以上;
  
  (二)以批发交易为主,能够跨区域吸引生产商、批发商和大宗用户,交易商品辐射全国或者主要产销区,能逐步实现与国际市场在信息、价格等方面接轨,对所在行业产销影响较大,并发挥导向作用;
  
  (三)年交易额在全国同类商品交易市场中位居前5名;
  
  (四)组织机构、规章制度健全,运作规范;
  
  (五)自觉贯彻执行国家的方针政策,近2年没有违法违纪行为。

  四、申报重点联系市场应当提交下列材料
  
  (一)市场申请报告和省级商务主管部门的初审意见;
  
  (二)申报单位基本情况表(附件);
  
  (三)市场章程、交易规则和内部管理制度等文件;
  
  (四)各地市场建设管理部门批准设立的文件(复印件)。

  五、申报重点联系市场的程序
  
  (一)地方开办的具备上述条件的商品交易市场,可以向市场所在地的省级商务主管部门申请,由省级商务主管部门初审后向商务部申报。

  (二)原国家经贸委、原国家国内贸易局、中国物流与采购联合会公布的重点联系市场,统一纳入商务部重点联系市场,并按照上述程序重新申报。

  (三)生产资料批发交易市场,可以向中国物流与采购联合会申请,由中国物流与采购联合会初审后,向商务部申报。

  (四)商务部根据各地申报情况,在严格筛选、综合平衡及征求中国物流与采购联合会等行业协会意见的基础上,确定并公布商务部联系的重点联系市场名单。

  各省级商务主管部门应于2004年12月15日前将申报单位基本情况表及推荐函报商务部市场体系建设司。

  联系人:孙 勇、李党会
  电话:010-85226396、85186397
  传 真:65121070

  附件:申报单位基本情况表

                          二OO四年十月二十五日

黑河市室内装饰行业管理暂行规定

黑龙江省黑河市人民政府


第9号


《黑河市室内装饰行业管理暂行规定》业经2001年9月6日—7日市政府第10次市长常务会议讨论通过,现予发布实施。


市长:赵学礼

二OO一年十月二十九日



黑河市室内装饰行业管理暂行规定



第一章 总 则
第一条 为加强室内装饰行业管理,规范行业行为,维护室内装饰行业市场秩序,保障室内装饰企业和消费者的合法权益,促进装饰行业健康发展,根据国家有关规定,结合我市实际,制定本规定。
第二条 本规定所称的室内装饰,是指对人们活动的所有成型空间(含室内六壁表面)的再加工再创造,是一个包括室内空间及相关环境的装饰设计、施工、室内用品配套生产,组套供应的集技术、艺术、劳务和工程服务于一体的系统工程。
第三条 本规定适用于黑河市行政区域内一切成形室内空间装饰工程设计、施工及相关的配套用品、陈设品的供应、设备安装及环境美化的企事业单位和个体经营者。
第四条 黑河市经济贸易委员会是室内装饰行业的主管部门,黑河市室内装饰行业管理办公室具体负责全市室内装饰的行业监督管理。其职责是:
(一) 审查、核发室内装饰行业设计、施工单位的资质等级证书和施工、生产、经营许可证;
(二) 审查、核发设计、施工单位出入境施工许可证和室内装饰工程施工许可证;
(三) 监督管理室内装饰工程的发包、承包和招标、投标工作;
(四) 会同有关部门监督、验收、评估室内装饰设计、施工工程质量,安全标准和工程预算、决算、定额取费标准的执行情况;
(五) 会同有关部门依法查处室内装饰设计、施工及装饰材料生产、经营中的违法行为,维护室内装饰行业市场秩序;
(六) 受理消费者对室内装饰工程质量投诉,协调处理室内装饰活动中的纠纷;
(七) 组织培训室内装饰设计、施工等各种专业人员,组织评定室内装饰人员的专业资格,建立健全持证上岗制度,提高队伍素质;
(八) 组织开展室内装饰设计方案、施工工程交流、创优、评优、奖励活动;
(九) 加强对室内装饰行业的宣传,增强公众对室内环境、室内卫生、室内安全的全面认识,正确引导消费;
(十) 法律、法规、规章所赋予的其它职责。
第五条 市工商、技术监督、公安、城建、财政、税务、物价等部门应按照各自职能,协同做好室内装饰行业的管理工作。

第二章 资质等级、许可证的申请、核发和管理

第六条 从事室内装饰设计、施工的单位必须取得室内装饰行业管理部门审查、核发的资质等级证书。在资质等级许可的范围内承揽室内装饰工程、从事室内装饰经营。无资质等级证书的设计、施工单位,一律不准承揽室内装饰及相关的设计、施工工程。
第七条 新开办的室内装饰、设计单位和生产、经营企业,必须取得资质等级证书或生产、经营许可证后办理工商营业执照。
已取得营业执照的从事室内装饰设计、施工单位,必须按本规定补办资质等级证书。
第八条 凡从事室内装饰设计、施工的单位,必须具备以下条件:
(一)有企业名称、管理机构和固定场所;
(二)有与经营范围相适应的技术人员和管理人员;
(三)有与经营范围相适应的生产机具、设备和资金;
(四)经济独立核算,有健全的经营管理制度和财务制度。
第九条 室内装饰设计、施工单位的《资质等级证》分为甲、乙、丙、丁四级,丁级资质又分为一、二两个等级。各级资质等级的认定及营业范围按《全国室内装饰设计单位、施工企业管理规定》办理。
第十条 申请资质等级证书的,均应由室内装饰行业管理部门审查、核发。
第十一条 既设计又施工的单位,应分别进行资质审查。在申报资质等级时,人、财、物条件可以互用,但设计、施工的经历不能相互代替。
第十二条 室内装饰设计、施工单位改变名称、法定代表人、企业分立、合并、歇业、解散、撤消的,应在变更后30日内向原资质审批部门办理变更登记或注销手续。
第十三条 不能取得资质等级证书,但有承担小型室内装饰(装潢、装修)业能力的个体业者,应到市室内装饰行业管理部门办理施工许可证。3人以上固定施工者,应到工商部门办理营业执照。
第十四条 从事装饰材料生产与组套供应的生产、经营单位及个体业者,应到市室内装饰行业管理部门办理生产、经营许可证。
第十五条 资质等级证书及施工、生产、经营许可必须按期接受发证部门的证书复查和年检,逾期不接受资质复查和年检的公布失效。

第三章 监督与管理

第十六条 室内装饰设计、施工单位应当依法经营,严格执行工艺规程和质量标准,保证工程设计和施工质量。
第十七条 凡在本市从事室内装饰设计、施工单位和个体经营者在承揽施工任务时,须持资质等级证书副本、工商执照副本、工程承包合同,公共场所的室内装饰还必须持消防安全审核意见书、工程设计图纸等,到市室内装饰行业管理部门进行验证、登记和领取《施工许可证》,未取得施工许可证,不得从事室内装饰工程。
第十八条 室内装饰设计、施工单位和个体经营者均须向市室内装饰行业管理部门交纳管理费。
第十九条 室内装饰设计、施工单位不得以不正当竞争手段承揽工程,不得超越资质等级许可的范围承揽工程。
甲、乙、丙级施工企业承包的室内装饰工程根据需要可分包,但主体部分必须自行完成,分包部分不得超过工程总造价的二分之一。丁级施工企业承包的工程不得分包。严禁施工企业倒手转包工程。
第二十条 两个以上施工单位联合承包施工任务时,其业务范围以等级高的企业为准并负技术和质量责任。参加联合的企业不准超过3个。
第二十一条 室内装饰活动应本着公平、公开的原则,凡投资总额在30万元以上(含30万元)的新建、改建、扩建和改造的室内装饰工程,除特殊工程外,均应实行公开招标、投标。
第二十二条 市室内装饰行业管理办公室负责本市室内装饰工程招标投标的管理工作。具体管理细则由市室内装饰行业管理办公室制定。
第二十三条 室内装饰设计、施工单位应严格按中国轻工总会、国家技术监督局联合发布的《室内装饰工艺规程和质量验收办法》、QB1838-93《室内装饰工程质量规范》和《建筑内部装修设计防火规范》的规定进行设计施工。施工中确需改变设计图纸的,须经有关部门批准。
第二十四条 任何单位和企业不得以任何理由拒绝室内装饰质量监督检验。
第二十五条 凡投资在30万元以上的室内装饰工程完工后,必须经室内装饰行业管理部门会同有关部门组织工程质量验收,合格后方可交付使用。
第二十六条 室内装饰设计、施工单位应当执行国家规定的室内装饰工程预算定额和室内装饰设计收费标准,不准高估冒算、哄抬造价,严禁以次充好、偷工减料。
第二十七条 室内装饰材料的生产与组套供应的生产与经营单位及个人,要接受室内装饰管理部门的监督与管理。
第二十八条 室内装饰设计、施工必须保证房屋结构安全。对原有建筑物拆改主体结构、设备或明显加大荷载的室内装饰工程,建设单位必须按有关部门的规定报批,未经有关部门批准,不得施工;已确定为危房的,不得进行室内装饰施工;施工现场必须符合环境保护要求。
第二十九条 外埠(含国外)室内装饰设计、施工单位到我市承包、分包室内装饰工程设计或施工的,应持当地室内装饰行业主管部门出具的外出施工证明、资质等级证书、工商执照等有关手续到市室内装饰行业主管部门办理《施工许可证》。异地施工(含出境)必须到装饰行业管理办公室办理有关手续。
第三十条 室内装饰工程实行限期保修制度,单位不少于一年,住宅不少于半年,维修费用由责任方承担。

第四章 法律责任

第三十一条 违反本规定,有下列行为之一的,由市室内装饰行业管理部门会同有关部门根据情节轻重,分别给予警告、责令停止施工,降低资质等级等处罚,同时可并处室内装饰工程总造价或销售总额2%—4%的罚款。构成犯罪的,由司法机关追究刑事责任。
(一)未取得室内装饰设计、施工资质等级证书和许可证而进行室内装饰设计、施工、装饰材料用品生产和经营的;
(二)超越室内装饰资质等级和营业范围承揽工程的;
(三)涂改、伪造、转借、出卖资质证书和许可证书的;
(四)采取不正当手段承揽工程的;
(五)倒手转包室内装饰工程或违反规定分包工程从中渔利的;
(六)应公开招标发包而未按规定进行招标的;
(七)将设计、施工发包给超出资质等级范围企业的;
(八)在室内装饰活动中偷工减料、高估冒算、以次充好、以假充真骗取高额利润的;
(九)未经批准在施工中拆改房屋主体结构、设备或明显加大荷载,或在危房内进行装饰施工的;
(十)拒绝室内装饰质量监督检验机构监督检查;未经室内装饰行业管理部门和有关部门验收或不合格工程交付使用的;
(十一)扰乱室内装饰市场秩序,妨碍室内建设单位及装饰行业管理机构依法执行公务的;
(十二)家庭装饰用户拒不执行本规定,乱拆乱装或擅自将工程交给不具备设计、施工条件企业的;
第三十二条 室内装饰设计、施工单位和个人违反消防安全规定的,由公安消防部门对直接责任人或责任单位依法进行处罚。
第三十三条 当事人对行政处罚决定不服的,可以依法申请行政复议或直接向人民法院提起诉讼。逾期既不申请复议,也不向法院起诉,又不履行处罚决定的,由做出处罚的机关申请法院强制执行。
第三十四条 室内装饰行业管理部门工作人员应严格执行国家政策、法规和有关规定,持证上岗、依法行政、廉洁自律、秉公办事、热情服务。对滥用职权、玩忽职守、徇私舞弊的,由主管部门或监察部门给予行政处分,构成犯罪的,由司法机关依法追究刑事责任。
第五章 附 则

第三十五条 本规定由市室内装饰行业主管部门负责解释。市辖各县(市)可参照本办法执行。
第三十六条 本规定自发布之日起执行。



Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.